急診PCI的若干問(wèn)題課件_第1頁(yè)
急診PCI的若干問(wèn)題課件_第2頁(yè)
急診PCI的若干問(wèn)題課件_第3頁(yè)
急診PCI的若干問(wèn)題課件_第4頁(yè)
急診PCI的若干問(wèn)題課件_第5頁(yè)
已閱讀5頁(yè)，還剩39頁(yè)未讀， 繼續(xù)免費(fèi)閱讀

下載本文檔

版權(quán)說(shuō)明：本文檔由用戶提供并上傳，收益歸屬內(nèi)容提供方，若內(nèi)容存在侵權(quán)，請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡(jiǎn)介

急診PCI的若干問(wèn)題急診PCI的若干問(wèn)題Endothelialprogenitorcell(EPC)capturingstentsHighdoseGPIIb/IIIainhibitorspre-hospitalizationManualthrombusaspiration(TA)duringPPCIPredictorsofstentthrombosisafterPPCI急診PCI的若干問(wèn)題Endothelialprogenitorcell(ERandomization50GenousTM50CrCo6-monthclinical,angio

&

IVUSFUGENIUS-STEMITrial2007.8-9,SinglecenterprospectiveASA100mg/day

+

clopidogrel75mg/day30daysGPIIb/IIIainhibitorsandthromboaspirationatthediscretionofthephysicianPresentedbyDr.PavelCervinkaatACC.09/i2,Orlando,FLRandomization50GenousTM50CrCGENIUS-STEMITrial6-monthclinicaloutcomeMACECVDeathsMITLRSTP=0.03P=NSP=0.04P=NSP=NSGenousTMCrCo2410PresentedbyDr.PavelCervinkaatACC.09/i2,Orlando,FLGENIUS-STEMITrialMACE

GENIUS-STEMITrialConclusionsTheuseofEPCcapturestentsinthesettingofSTEMIisfeasible

&

safe.RateofMACEat6-monthFUwassignificantlyhigherinGenousTMgroupthanCrCostents.WarrisomeistherateoflatestentthrombosisinEPCscapturestentgroup.Largerrandomizedtrialsaremandatory.PresentedbyDr.PavelCervinkaatACC.09/i2,Orlando,FLGENIUS-STEMITrialTheuseof直接PCI患者院前與導(dǎo)管室應(yīng)用大劑量替羅非班的比較ON-TIME-2研究AGIR-2研究直接PCI患者院前與導(dǎo)管室應(yīng)用Prospective,multicentre,placebo-controlled,randomisedSTEMI30min-24hrs5000UFH,500mgASA,600mgClopidogrelAngiogramTirofiban*PlaceboTransportationPCIcentreAngiogramTirofibanprovisionalTirofibancont’dON-TIME-2oneyrfollow-up

n=9842006.6-2007.11PPCI*Bolus:25μg/kg&0.15μg/kg/mininfusionFollow-upON-TIME-2ChristianW.Hammetal.Prospective,multicentre,placConclusionsHighdosetirofibanontopofclopidogrel(600mg)intheprehospitalsettingissafePre-Hospitalinitiationoftirofiban(HDB)improvesSTresolutionbefore&afterprimaryPCINoincreaseinbleedingriskImprovesoutcomeofprimaryPCIforAMIStrongtrendtoreducedmortalitycontinuesover1yearfollow-upInpatientsundergoingprimaryPCImortalityissignificantlylower.Highestefficacyinelderly(>65yrs),inKillipclass2andinearlypresenters.ON-TIME-2ChristianW.Hammetal.ConclusionsHighdosetirofibanMICUPatient

callSTEMIundergoingprimaryPCISTEMI20min-12h600mgclopidogrel250mgaspirinUFH60U/kgTirofiban

25μg/kgbolus,0.15ug/kgivgttAngiographyAngiographyPre-hospitalMICU

transportationCathlabRandomize

OpenLabelMedical

DispatcherTirofiban

25μg/kgbolus,0.15ug/kgivgttAGIR2(n=156)(n=156)PPCIEricBonnefoyetal.MICUPatient

callSTEMIundergoi0.61.20123456DeathSevereBleedingAcutestentthrombosisStrokeCathlabtirofibanPre-Hospitaltirofiban%p=NSp=NSp=NSp=NSIn-hospitaleventsP=NSOnadmission

toCathlabP=NSP=NSInitialTIMIgrade2-3STsegmentresolution>70%39.744.298.1978.715.255.452.6020406080100120%FinalTIMIgrade2-3P=NSCathlabtirofibanPre-hospitaltirofibanSurrogatesofreperfusionOnehr

afterPCIAGIR2ResultsandConclusionTheresultsdonotsupportthenecessitytoinitiatetirofibanadministrationinpre-hospitalsettingsEricBonnefoyetal.0.61.2012345急診PCI血栓抽吸裝置的應(yīng)用

Manualthrombusaspiration(TA)duringPPCIErythrocyte-richthrombiPlatelet/fibrin-richthrombiCombinedthrombiEdematouscomponentsAtheroscleroticcomponents45231454FreshFormalinfixedFormalinfixedHEHEYANhongbingetal.急診PCI血栓抽吸裝置的應(yīng)用

ManualthrombusTAPASand1-yearfollow-up0%1%2%3%4%5%6%7%8%AllcausemortalityCardiacdeathReinfarctionTAPAS1-yearfollow-upP=0.04P=0.02P=0.05AspConAspConAspConpatient0%20%40%60%80%100%45.717.126.3AspConMBG0-1MBG2MBG3MyocardialBlushGradeP＜0.00156.630.812.644.237.917.90%20%40%60%80%100%STR＜30%STR30-70%MBG＞70%AspConResolutionofST-segmentElevationP＜0.001VlaarP,etal.Lancet2008;371:1915-20;SvilaasT,etal.NEnglJ2008;358:557-676FExportaspirationcatheterintention-to-treattrialRoutineutilizationofTAn=535forTAn=536forconventionalPPCIFollow-upfor1yrTAPASand1-yearfollow-up4.77mortalityAmeta-analysisofadjunctivethrombectomyandembolicprotectiondevicesinSTEMI1996-200830randomizedtrialsn=6415patients＜12hnativevesselSTEMIEndpoints:

AllcausemortalityMACEStrokeBavryAA.etal.,EuropeanHeartJ.2008;29:2989–30016month5month4month13trialsn=30265trialsn=93412trialsn=2442mortalityAmeta-analysisofad＜12hSTEMITIMI0-1n=49successfulaspirationwithvisiblematerialDIVERCEandZEEKYANhongbingetal.0.590.520.480.50.520.540.560.580.6146257.9050100150200250300PresenceofplaquematerialPresenceofthrombusonlyPresenceofplaquematerialPresenceofthrombusonlyLVEF16hrpost-proceduralP＜0.02P＜0.02PeakCK-MBpost-proceduraln=28n=28n=21n=28n=21PlaquematerialRemovingplaquematerialsfromtheculpritlesionis

beneficialShouldTAberoutinelyperformedinTIMI2-3patients?Needstrials＜12hSTEMIYANhongbingetalArethereanydifferencesofdevicesoperabilityandclinicalimpactsamongdifferenttypeaspirationcatheters?YANhongbingetal.ChinMedJ2009;122(6):648-654SizedistributionofthrombiP=0.02forsmall,P=0.09formoderateandP=0.03forlargethrombi.

largesmallmoderateFrequencyofdual-wiresArethereanydifferencesofdClinicalimpactsofDiverCEvsZEEKYANhongbingetal.ChinMedJ2009;122(6):648-654ClinicalimpactsofDiverCEvAMI直接PCI支架血栓的預(yù)測(cè)因素：

HORIZONS-AMI試驗(yàn)AMI直接PCI支架血栓的預(yù)測(cè)因素：

HORIZONS-AMNolimitationsfordrug-elutingstentsinSTEMIpatients1yr

EndpointsDESTaxus,n=2257(%)BMSExpress,n=749(%)Hazardratio(95%CI)Ischemictargetlesionrevascularization9(0.43–0.83)SafetyMACE8.18.01.02(0.76–1.36)All-causemortality9(0.64–1.55)MI1(0.54–3.22)Stroke1.00.71.52(0.58–4.00)Stentthrombosis2(0.58–1.45)Binaryrestenosis,perlesion,at13mo10.022.90.44(0.33–0.57)TCT2008:TranscatheterCardiovascularTherapeutics20thAnnualScientificSymposiumOctober12-17,2008,Washington,DCEndpointsNolimitationsfordrug-elutinIndependentPredictorsofST(CoxModel)AcuteSTSubacuteSTLateSTIndependentPredictorsofST(ConclusionsAcute,subacute&lateSTappeartoberelatedtodifferentfactorsthemostimportantpredictorsofacute&subacuteSTevents:Pharmacologicaltherapy,vesselflow,lesioncharacteristics&number&lengthofstentsthemostimportantpredictorsoflateSTevents:Patientrelatedfactorsincludingcigarettesmoking&priorMIThetypeofstentimplanted(DESvs.BMS)wasnotrelatedtoSTduringanytimeintervalupto1-yearSTwithin1-yearoccurredwithsimilarfrequencyinpatientstreatedwithUFH+GPI&bivalirudinaloneHowever,acuteSTwasmorecommonwithbivalirudin,especiallywithinthe1st5hours,whereasSTtendedtobelesscommonwithbivalirudinthanwithUFH+GPIbetween24hours&1-yearConclusionsAcute,subacute&lThankyou!Thankyou!GENIUS-STEMI

Trial6monthangio&IVUSdata

Genous

Cr-Co

PvalueANGIODATA

N=44N=47Latelumenloss(mm)0.89±0.590.79±0.47NSRestenosis(>50%)2013NS

(QCA:PieMedicalIm)IVUSN=41N=42meanin-stentNIH(mm3)49.7±48

40.0±22.8NS

(Volcano,pullback0.5%mm/s)(QIVAPieMedicalIm)

NIH:NeointimalhyperplasiainsidethestentGENIUS-STEMITrial急診PCI的若干問(wèn)題急診PCI的若干問(wèn)題Endothelialprogenitorcell(EPC)capturingstentsHighdoseGPIIb/IIIainhibitorspre-hospitalizationManualthrombusaspiration(TA)duringPPCIPredictorsofstentthrombosisafterPPCI急診PCI的若干問(wèn)題Endothelialprogenitorcell(ERandomization50GenousTM50CrCo6-monthclinical,angio

&

IVUSFUGENIUS-STEMITrial2007.8-9,SinglecenterprospectiveASA100mg/day

+

clopidogrel75mg/day30daysGPIIb/IIIainhibitorsandthromboaspirationatthediscretionofthephysicianPresentedbyDr.PavelCervinkaatACC.09/i2,Orlando,FLRandomization50GenousTM50CrCGENIUS-STEMITrial6-monthclinicaloutcomeMACECVDeathsMITLRSTP=0.03P=NSP=0.04P=NSP=NSGenousTMCrCo2410PresentedbyDr.PavelCervinkaatACC.09/i2,Orlando,FLGENIUS-STEMITrialMACE

GENIUS-STEMITrialConclusionsTheuseofEPCcapturestentsinthesettingofSTEMIisfeasible

&

safe.RateofMACEat6-monthFUwassignificantlyhigherinGenousTMgroupthanCrCostents.WarrisomeistherateoflatestentthrombosisinEPCscapturestentgroup.Largerrandomizedtrialsaremandatory.PresentedbyDr.PavelCervinkaatACC.09/i2,Orlando,FLGENIUS-STEMITrialTheuseof直接PCI患者院前與導(dǎo)管室應(yīng)用大劑量替羅非班的比較ON-TIME-2研究AGIR-2研究直接PCI患者院前與導(dǎo)管室應(yīng)用Prospective,multicentre,placebo-controlled,randomisedSTEMI30min-24hrs5000UFH,500mgASA,600mgClopidogrelAngiogramTirofiban*PlaceboTransportationPCIcentreAngiogramTirofibanprovisionalTirofibancont’dON-TIME-2oneyrfollow-up

n=9842006.6-2007.11PPCI*Bolus:25μg/kg&0.15μg/kg/mininfusionFollow-upON-TIME-2ChristianW.Hammetal.Prospective,multicentre,placConclusionsHighdosetirofibanontopofclopidogrel(600mg)intheprehospitalsettingissafePre-Hospitalinitiationoftirofiban(HDB)improvesSTresolutionbefore&afterprimaryPCINoincreaseinbleedingriskImprovesoutcomeofprimaryPCIforAMIStrongtrendtoreducedmortalitycontinuesover1yearfollow-upInpatientsundergoingprimaryPCImortalityissignificantlylower.Highestefficacyinelderly(>65yrs),inKillipclass2andinearlypresenters.ON-TIME-2ChristianW.Hammetal.ConclusionsHighdosetirofibanMICUPatient

callSTEMIundergoingprimaryPCISTEMI20min-12h600mgclopidogrel250mgaspirinUFH60U/kgTirofiban

25μg/kgbolus,0.15ug/kgivgttAngiographyAngiographyPre-hospitalMICU

transportationCathlabRandomize

OpenLabelMedical

DispatcherTirofiban

25μg/kgbolus,0.15ug/kgivgttAGIR2(n=156)(n=156)PPCIEricBonnefoyetal.MICUPatient

callSTEMIundergoi0.61.20123456DeathSevereBleedingAcutestentthrombosisStrokeCathlabtirofibanPre-Hospitaltirofiban%p=NSp=NSp=NSp=NSIn-hospitaleventsP=NSOnadmission

toCathlabP=NSP=NSInitialTIMIgrade2-3STsegmentresolution>70%39.744.298.1978.715.255.452.6020406080100120%FinalTIMIgrade2-3P=NSCathlabtirofibanPre-hospitaltirofibanSurrogatesofreperfusionOnehr

afterPCIAGIR2ResultsandConclusionTheresultsdonotsupportthenecessitytoinitiatetirofibanadministrationinpre-hospitalsettingsEricBonnefoyetal.0.61.2012345急診PCI血栓抽吸裝置的應(yīng)用

Manualthrombusaspiration(TA)duringPPCIErythrocyte-richthrombiPlatelet/fibrin-richthrombiCombinedthrombiEdematouscomponentsAtheroscleroticcomponents45231454FreshFormalinfixedFormalinfixedHEHEYANhongbingetal.急診PCI血栓抽吸裝置的應(yīng)用

ManualthrombusTAPASand1-yearfollow-up0%1%2%3%4%5%6%7%8%AllcausemortalityCardiacdeathReinfarctionTAPAS1-yearfollow-upP=0.04P=0.02P=0.05AspConAspConAspConpatient0%20%40%60%80%100%45.717.126.3AspConMBG0-1MBG2MBG3MyocardialBlushGradeP＜0.00156.630.812.644.237.917.90%20%40%60%80%100%STR＜30%STR30-70%MBG＞70%AspConResolutionofST-segmentElevationP＜0.001VlaarP,etal.Lancet2008;371:1915-20;SvilaasT,etal.NEnglJ2008;358:557-676FExportaspirationcatheterintention-to-treattrialRoutineutilizationofTAn=535forTAn=536forconventionalPPCIFollow-upfor1yrTAPASand1-yearfollow-up4.77mortalityAmeta-analysisofadjunctivethrombectomyandembolicprotectiondevicesinSTEMI1996-200830randomizedtrialsn=6415patients＜12hnativevesselSTEMIEndpoints:

AllcausemortalityMACEStrokeBavryAA.etal.,EuropeanHeartJ.2008;29:2989–30016month5month4month13trialsn=30265trialsn=93412trialsn=2442mortalityAmeta-analysisofad＜12hSTEMITIMI0-1n=49successfulaspirationwithvisiblematerialDIVERCEandZEEKYANhongbingetal.0.590.520.480.50.520.540.560.580.6146257.9050100150200250300PresenceofplaquematerialPresenceofthrombusonlyPresenceofplaquematerialPresenceofthrombusonlyLVEF16hrpost-proceduralP＜0.02P＜0.02PeakCK-MBpost-proceduraln=28n=28n=21n=28n=21PlaquematerialRemovingplaquematerialsfromtheculpritlesionis

beneficialShouldTAberoutinelyperformedinTIMI2-3patients?Needstrials＜12hSTEMIYANhongbingetalArethereanydifferencesofdevicesoperabilityandclinicalimpactsamongdifferenttypeaspirationcatheters?YANhongbingetal.ChinMedJ2009;122(6):648-654SizedistributionofthrombiP=0.02forsmall,P=0.09formoderateandP=0.03forlargethrombi.

largesmallmoderateFrequencyofdual-wiresArethereanydifferencesofdClinicalimpactsofDiverCEvsZEEKYANhongbingetal.ChinMedJ2009;122(6):648-654ClinicalimpactsofDiverCEvAMI直接PCI支架血栓的預(yù)測(cè)因素：

HORIZONS-AMI試驗(yàn)AMI直接PCI支架血栓的預(yù)測(cè)因素：

HORIZONS-AMNolimitationsfordrug-elutingstentsinSTEMIpatients1yr

EndpointsDESTaxus,n=2257(%)BMSExpress,n=749(%)Hazardratio(95%CI)Ischemictargetlesionrevascularization9(0.43–0.83)SafetyMACE8.18.01.02(0.76–1.36)All-causemortality9(0.64–1.55)MI1(0.54–3.22)Stroke1.00.71.52(0.58–4.00)Stentthrombosis2(0.58–1.45)Binaryrestenosis,perlesion,at13mo10.022.90.44(0.33–0.57)TCT2008:TranscatheterCardiovascularTherapeutics20thAnnualScientificSymposiumOctober12-17,2008,Washington,DCEndpointsNolimitationsfordrug-elutinIndependentPredictorsofST(CoxModel)AcuteSTSubacuteSTLateSTIndependentPredictorsofST(ConclusionsAcute,subacute&lateSTappear

溫馨提示

  • 1. 本站所有資源如無(wú)特殊說(shuō)明，都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等，如果需要附件，請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙，網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽，若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間，僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理，對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯，并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容，請(qǐng)與我們聯(lián)系，我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。

評(píng)論

0/150

提交評(píng)論